Re-appointment of Dr. Kirtikumar Mehta (DIN: 00385658) as the Non Executive Director and Chairman of the Company for the term of five consecutive Financial Years with effective from April 01, 2027
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Corona Remedies Limited reported strong FY2026 results with revenue from operations of Rs 1,403.18 Crores, up ~17.3% from Rs 1,196.42 Crores in FY2025. Net profit after tax stood at Rs 184.85 Crores (standalone) and Rs 185.12 Crores (consolidated), both up ~24% YoY. The Board recommended a final dividend of Rs 10 per share (100% payout) with record date June 19, 2026. Several auditor appointments were approved: Walker Chandiok & Co LLP as new statutory auditor for 5 years, Dhara Patel as secretarial auditor, Shah & Shah Associates as internal auditor, and Manish B. Analkat as cost auditor — all subject to shareholder approval. Additionally, Dr. Kirtikumar Mehta (DIN: 00385658) is being reappointed as Non Executive Director and Chairman for 5 years from April 1, 2027. The company listed on NSE and BSE via IPO in December 2025.
Solid financial performance with ~17% revenue growth and ~24% PAT growth reflects healthy operational momentum. Dividend payout is encouraging for shareholders. The leadership continuity with Mehta's reappointment provides governance stability.